Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc > acasti

<< Previous

Bullboard Posts

Next >>

Comment by Francine01on Aug 14, 2020 3:07pm

316 Views

Post# 31410115

RE:acasti

Management is fully aware of the china market. they had a $125M deal in 2017 for the China market. They decided ph3 results to gamble that the value would significantly more than the offer on the table. After T2 results, only god knows what will be the outcome for an NDA and China market.

My view is that Acasti is at the bottom and all bad news are fully priced. T2 will be better and we could only speculate if they could still filled an NDA based on the T1 & T2 combined.

GLTA.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China